# Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

> **NCT04839354** · PHASE3 · COMPLETED · sponsor: **Claudia R. Morris** · enrollment: 271 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** L-Arginine Hydrochloride
- **OTHER:** Normal saline

## Key facts

- **NCT ID:** NCT04839354
- **Lead sponsor:** Claudia R. Morris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-21
- **Primary completion:** 2024-07-11
- **Final completion:** 2024-07-11
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04839354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04839354, "Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04839354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*